ANR / ERDERA 2027: collaborative research on recently identified rare diseases
Catalyse collaborative research on recently identified rare diseases that remain scientifically under-explored.
At a glance
- Programme
- ERDERA, third call (ERDERA 2027)
- Territory
- 21 countries announced, including France; participation of Portugal to be confirmed
- Beneficiaries
- Collaborative research projects; applicant eligibility, project composition and place of French companies to be confirmed in the call specifications
- Type of aid
- Research project funding; terms to be confirmed in the call specifications
- Amount / rate
- Not disclosed in the pre-announcement; to be confirmed in the call specifications
- Availability
- Pre-announcement; opening announced for December 2026
ERDERA is preparing its third call, ERDERA 2027, to catalyse new collaborative research initiatives on recently identified rare diseases that remain scientifically under-explored. ANR (the French National Research Agency) has published the pre-announcement, which gives dates only by month: opening in December 2026, closing in June 2027. It does not yet specify the eligible applicants, the expected composition of projects or the funding terms.
Which projects are funded?
The call aims to stimulate research interest in these diseases. By advancing understanding of their natural history and mechanisms, and by encouraging the development of relevant models, it seeks above all to generate the basic knowledge needed to accelerate the future development of therapies.
To be eligible, the disease studied must meet both of the following criteria:
- have been reported for the first time in the peer-reviewed literature on or after 1 January 2010, including its association with a suspected causal mechanism (for example a gene-disease association); applicants provide the main publication reporting it;
- be registered in Orphanet, or be in the process of registration, at the time of application; for a disease not yet registered, applicants prove that registration has been requested and give the planned timetable.
A project may focus on a single disease or on a small group of closely related diseases (for example sharing a family of causative genes or a pathway), provided each one meets both criteria.
Proposals should cover at least one of the following areas:
- natural history studies and patient registries, including those designed to prepare future clinical trials; as far as possible, they integrate the development and application of patient-reported outcome measures, and the exploration of standardised health monitoring instruments and patient-entered data is encouraged;
- identification and validation of biomarkers of the pathophysiology or progression of the disease, including for patient stratification, characterisation of natural history or preparation of future clinical trials, provided they serve the understanding of mechanisms or the monitoring of the disease;
- development of in silico, cellular (the English version cites patient-derived iPSC models and organoids) and animal models that faithfully reproduce the human disease, including the creation, during the project, of models where none exist;
- elucidation of pathophysiological pathways, including studies aimed at identifying disease mechanisms likely to guide future therapeutic strategies.
The development of a biomarker-based test or assay intended for clinical diagnostic use is out of scope.
Who can apply?
The pre-announcement does not yet specify who can apply, or how many partners or countries a project must bring together. It gives the list of participating countries: Austria, Belgium, Bulgaria, Canada, Spain, Estonia, France, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal (participation to be confirmed), the Czech Republic, Romania, Slovakia, Sweden and Turkey.
The title of the call highlights collaborative research, but the pre-announcement does not say whether, or on what conditions, a French company can be funded: to be confirmed in the call specifications.
Which costs are eligible?
The pre-announcement does not specify eligible costs: they are to be confirmed in the call specifications.
How much funding is available?
No amount, rate, ceiling or project duration has been disclosed at this stage. The funding available to a French partner is to be confirmed in the call specifications.
Main selection criteria
The evaluation grid has not been published. The conditions set out in the pre-announcement nevertheless give some pointers:
- the eligibility of each disease studied with regard to the two criteria (first description on or after 1 January 2010, Orphanet registration);
- the project's fit with at least one of the call's four research areas;
- the contribution to basic knowledge of the natural history, mechanisms and models of the disease, with a view to the future development of therapies;
- the collaborative dimension of the project.
Points to watch
- This is a pre-announcement: dates are given only by month (opening in December 2026, closing in June 2027) and remain to be confirmed at launch.
- Eligibility depends first on the disease: each one must have been reported for the first time on or after 1 January 2010 and be listed in Orphanet, or be in the process of registration.
- The French and English versions differ on the proof required for a disease in the process of registration: a request "submitted to and acknowledged by Orphanet" (that is, submitted to Orphanet, which has acknowledged receipt) in English, proof that registration "has been requested and approved" in French. The English version also asks for the PMID or DOI of the main publication and, if available, the disease's OMIM or MONDO identifier. Check the final wording of the call text.
- Portugal's participation is not yet confirmed.
- Do not confuse this call with the EP PerMed 2027 (cell and gene therapy) and ERA4Health 2027 (nanotechnologies for diagnosis) calls, also in the catalogue: ERDERA 2027 targets basic knowledge on recently identified rare diseases and excludes the development of clinical diagnostic tests.
The CHOICE view
This call concerns teams already working on a recently described rare disease who can deepen knowledge of its natural history, biomarkers, models or mechanisms. It is not suited to a clinical diagnostic test project, which is out of scope. The first point to secure is the eligibility of the disease, which can be documented now: reference publication, Orphanet registration. For a company, it will then be necessary to check, as soon as the rules are published, that it can be funded as a French partner. Until then, CHOICE recommends building the partnership and the scientific positioning, without finalising a budget.
How to prepare your project
- Check the date of first description of each target disease and gather the main publication (with its PMID or DOI, and the disease's OMIM or MONDO identifier if available).
- Check the disease's registration in Orphanet or, failing that, initiate the request and keep proof of it.
- Choose the target research area or areas from the call's four.
- Identify the project partners and check that their country is among the participating countries.
- Register for the information webinar, the link to which appears on the pre-announcement, and contact ANR's ERDERA contact point.
- Check the eligibility and funding rules as soon as the call text is published.
Official sources
The conditions of a scheme can change. This fact sheet was checked on the date shown; only the call specifications, the official texts and the funding body's decision are authoritative.
How CHOICE works on this kind of application
Finding the right scheme is only one step. What matters happens before: clarifying the project, gathering the expected evidence, bringing in the right partners and sequencing commitments.
- Our approach Improve and de-risk the project before financing it.
- Our services Assessment, business plan, preparing and filing the application, representation, follow-up.
- Our references More than 130 projects supported over ten years, and the firm's accreditations.
- What a letter of support really proves Also worth reading in our publications.
- All academic research calls The full catalogue, with conditions and deadlines.